The most frequently reported caplacizumab-related TEAEs (in ≥ 5% of participants) were increased alanine aminotransferase, epistaxis, and gastrointestinal hemorrhage, which occurred in two participants (9.5%) each. The gene discussed is GPT; the disease is Gastrointestinal hemorrhage.